TNF and COVID-19: Table 1 shows the general and clinical characteristics of patients treated with anti-TNFα (n = 313). The mean age of the considered population (SD) was 57 years (17.5). It was found that most of the selected patients (n = 135) were on Adalimumab treatment. Of these patients, 52.6% were male and 47.4% female. In addition, 15.6% (n = 21) tested positive for COVID-19 with this treatment regimen, but none were hospitalized or died.